Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Rheumatology
•
Osteoporosis
•
Endocrinology
•
Bone and Calcium Disorders
When discontinuing Denosumab after more than 2-3 years of therapy, when do you recommend giving the first dose of zoledronic acid?
Answer from: at Academic Institution
My practice has been that after 2-3 years of denosumab, I wait 6 months and then start zoledronic acid.
Sign in or Register to read more
Answer from: at Community Practice
Six months after the last injection.
Sign in or Register to read more
24261
24290
Related Questions
Would you consider anabolic osteoporosis therapy in a young adult male with multiple non-traumatic vertebral compression fractures and low bone density for age (Z-score -2.6)?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Would you stop denosumab in a patient with chronic kidney disease if they develop asymptomatic hypocalcemia after the injection?
What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?
How do you approach management of osteoporosis in patients post lung transplant?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
How would you approach a finding of osteoporosis (Z score -4.5) in a recently postpartum patient who had DEXA sent for long-term low-dose glucocorticoid use?
Would you consider PTH analogue in a patient with mildly elevated PTH?
How do you manage osteoporosis treatment following parathyroidectomy for primary hyperparathyroidism?
Is there any contraindication for use of Invisalign teeth aligners in patients undergoing treatment for osteoporosis?